Ethyl (E)-ferulate
Ethyl (E)-ferulate is an AMPK/Nrf2 signaling pathway activator that can reduce lipopolysaccharide (HY-D1056)-induced acute lung injury. Additionally, Ethyl (E)-ferulate exhibits free radical scavenging properties, providing anti-inflammatory, antioxidant, neuroprotective, and sunscreen effects. Ethyl (E)-ferulate holds promise for research in the fields of inflammation and neurodegenerative diseases.
For research use only. We do not sell to patients.
- CAS No.: 28028-62-8
- Formula: C12H14O4
- Molecular Weight:222.24
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All AMPK Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | GI50 |
1.2 μM
Compound: 11
|
Growth inhibition of human A549 cells by Sulforhodamine B assay
Growth inhibition of human A549 cells by Sulforhodamine B assay
|
[PMID: 21106458] |
| A549 | IC50 |
12.5 μM
Compound: 1b
|
Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
|
[PMID: 22954735] |
| Calu-1 | IC50 |
>50 μM
Compound: 1b
|
Cytotoxicity against human Calu1 cells after 72 hrs by alamar blue assay
Cytotoxicity against human Calu1 cells after 72 hrs by alamar blue assay
|
[PMID: 22954735] |
| HeLa | GI50 |
52.8 μM
Compound: 11
|
Growth inhibition of human HeLa cells by Sulforhodamine B assay
Growth inhibition of human HeLa cells by Sulforhodamine B assay
|
[PMID: 21106458] |
| HeLa | IC50 |
2.13 μM
Compound: 1b
|
Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay
Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay
|
[PMID: 22954735] |
| HOP-62 | IC50 |
26.8 μM
Compound: 1b
|
Cytotoxicity against human HOP62 cells after 72 hrs by alamar blue assay
Cytotoxicity against human HOP62 cells after 72 hrs by alamar blue assay
|
[PMID: 22954735] |
| LOX IMVI | IC50 |
>50 μM
Compound: 1b
|
Cytotoxicity against human LOXIMVI cells after 72 hrs by alamar blue assay
Cytotoxicity against human LOXIMVI cells after 72 hrs by alamar blue assay
|
[PMID: 22954735] |
| M14 | IC50 |
>50 μM
Compound: 1b
|
Cytotoxicity against human M14 cells after 72 hrs by alamar blue assay
Cytotoxicity against human M14 cells after 72 hrs by alamar blue assay
|
[PMID: 22954735] |
| MCF7 | GI50 |
86.3 μM
Compound: 11
|
Growth inhibition of human MCF7 cells by Sulforhodamine B assay
Growth inhibition of human MCF7 cells by Sulforhodamine B assay
|
[PMID: 21106458] |
| MT4 | CC50 |
>10 μM
Compound: 9
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay
|
[PMID: 26756779] |
| MT4 | EC50 |
>10 μM
Compound: 9
|
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay
|
[PMID: 26756779] |
| NCI-H1299 | IC50 |
36.8 μM
Compound: 1b
|
Cytotoxicity against human NCI-H1299 cells after 72 hrs by alamar blue assay
Cytotoxicity against human NCI-H1299 cells after 72 hrs by alamar blue assay
|
[PMID: 22954735] |
| NCI-H157 | IC50 |
32.3 μM
Compound: 1b
|
Cytotoxicity against human NCI-H157 cells after 72 hrs by alamar blue assay
Cytotoxicity against human NCI-H157 cells after 72 hrs by alamar blue assay
|
[PMID: 22954735] |
| NCI-H1792 | IC50 |
25.6 μM
Compound: 1b
|
Cytotoxicity against human NCI-H1792 cells after 72 hrs by alamar blue assay
Cytotoxicity against human NCI-H1792 cells after 72 hrs by alamar blue assay
|
[PMID: 22954735] |
| NCI-H460 | IC50 |
29.1 μM
Compound: 1b
|
Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay
Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay
|
[PMID: 22954735] |
| Platelet | IC50 |
193.2 μM
Compound: Ethyl ferulate
|
Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry
Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry
|
10.1039/C4MD00022F |
| SK-N-SH | GI50 |
22.3 μM
Compound: 11
|
Growth inhibition of human SK-N-SH cells by Sulforhodamine B assay
Growth inhibition of human SK-N-SH cells by Sulforhodamine B assay
|
[PMID: 21106458] |
Chemical Information
-
CAS No. 28028-62-8
-
Molecular Weight 222.24
-
Formula C12H14O4
-
SMILES
CCOC(/C=C/C1=CC(OC)=C(C=C1)O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
Purity & Documentation
References
[1]. Wu YX, et al. Ethyl ferulate protects against lipopolysaccharide-induced acute lung injury by activating AMPK/Nrf2 signaling pathway. Acta Pharmacol Sin. 2021 Dec;42(12):2069-2081. [Content Brief]
[2]. Nazaré A C, et al. Ethyl ferulate, a component with anti-inflammatory properties for emulsion-based creams[J]. Molecules, 2014, 19(6): 8124-8139. [Content Brief]
[3]. Cunha FVM, et al. Systematic review and technological prospection: ethyl ferulate, a phenylpropanoid with antioxidant and neuroprotective actions. Expert Opin Ther Pat. 2019 Feb;29(2):73-83. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)